Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVFMNASDAQ:FLXNNASDAQ:KMDANASDAQ:OCULNASDAQ:TXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVFMEvofem Biosciences$0.01$0.01$0.01▼$0.02$1.19M-0.92435,993 shs39,482 shsFLXNFlexion Therapeutics$25.08$9.20$4.30▼$13.66$1.26B1.531.18 million shs2 shsKMDAKamada$7.76+0.2%$7.03$5.08▼$9.16$453.14M0.9696,622 shs23,331 shsOCULOcular Therapeutix$9.36-1.1%$8.19$5.79▼$11.78$1.53B1.431.41 million shs1.16 million shsTXMDTherapeuticsMD$1.12-1.8%$1.28$0.70▼$2.44$13.66M0.59160,893 shs22,462 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVFMEvofem Biosciences0.00%+6.38%+6.38%+3.09%+4.71%FLXNFlexion Therapeutics+175.00%+175.00%+175.00%+175.00%+175.00%KMDAKamada0.00%+0.60%+16.46%+29.48%+50.60%OCULOcular Therapeutix0.00%+1.52%+11.69%+47.17%+39.91%TXMDTherapeuticsMD0.00%0.00%-0.88%+26.67%-28.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVFMEvofem Biosciences0.5997 of 5 stars0.03.00.04.80.00.00.0FLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKMDAKamada4.0542 of 5 stars3.33.00.00.03.21.73.1OCULOcular Therapeutix3.9429 of 5 stars3.51.00.04.12.72.50.0TXMDTherapeuticsMD0.8585 of 5 stars0.05.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVFMEvofem Biosciences 0.00N/AN/AN/AFLXNFlexion Therapeutics 0.00N/AN/AN/AKMDAKamada 2.67Moderate Buy$13.0067.61% UpsideOCULOcular Therapeutix 3.00Buy$17.3385.19% UpsideTXMDTherapeuticsMD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OCUL, TXMD, EVFM, KMDA, and FLXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/15/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/8/2025KMDAKamadaSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/8/2025OCULOcular TherapeutixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/8/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVFMEvofem Biosciences$11.39M0.10N/AN/A($2.64) per share0.00FLXNFlexion Therapeutics$85.55M14.75N/AN/A($0.34) per share-73.76KMDAKamada$160.95M2.77$0.48 per share16.03$4.51 per share1.72OCULOcular Therapeutix$63.72M23.40N/AN/A$2.01 per share4.66TXMDTherapeuticsMD$1.76M7.36N/AN/A$2.37 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVFMEvofem Biosciences$52.98M-$0.05N/A∞N/A-46.42%-91.97%-61.93%N/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AKMDAKamada$14.46M$0.2926.7424.240.969.60%6.31%4.43%8/13/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.15N/AN/AN/A-323.09%-59.92%-41.98%8/6/2025 (Estimated)TXMDTherapeuticsMD-$2.18MN/A0.00∞N/A-114.07%-7.86%-5.46%8/11/2025 (Estimated)Latest OCUL, TXMD, EVFM, KMDA, and FLXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KMDAKamada$0.07$0.07N/A$0.07$154.06 million$44.02 million5/13/2025Q1 2025TXMDTherapeuticsMDN/A-$0.06N/A-$0.06N/A$0.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVFMEvofem BiosciencesN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVFMEvofem BiosciencesN/A0.110.09FLXNFlexion TherapeuticsN/A4.384.05KMDAKamadaN/A3.301.93OCULOcular Therapeutix0.2610.2210.14TXMDTherapeuticsMDN/A2.642.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVFMEvofem Biosciences0.22%FLXNFlexion Therapeutics90.01%KMDAKamada20.38%OCULOcular Therapeutix59.21%TXMDTherapeuticsMD30.74%Insider OwnershipCompanyInsider OwnershipEVFMEvofem Biosciences0.21%FLXNFlexion Therapeutics9.13%KMDAKamada36.10%OCULOcular Therapeutix2.30%TXMDTherapeuticsMD2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableFLXNFlexion Therapeutics25750.32 million45.73 millionNo DataKMDAKamada36057.51 million36.75 millionOptionableOCULOcular Therapeutix230159.30 million155.64 millionOptionableTXMDTherapeuticsMD42011.57 million11.31 millionOptionableOCUL, TXMD, EVFM, KMDA, and FLXN HeadlinesRecent News About These CompaniesMarlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street JournalJune 29, 2025 | wsj.comMayne Pharma Files Legal Complaint Against TherapeuticsMDJune 1, 2025 | tipranks.comTherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comTherapeuticsMD Inc. stock rises Monday, still underperforms marketMay 12, 2025 | marketwatch.comTherapeuticsMD Inc. stock outperforms competitors despite losses on the dayApril 8, 2025 | marketwatch.comTherapeuticsMD Announces Full Year 2024 Financial ResultsMarch 27, 2025 | businesswire.comTherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo FinanceMarch 26, 2025 | finance.yahoo.comTherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?January 7, 2025 | bovnews.comBTherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True PotentialJanuary 3, 2025 | bovnews.comBTherapeuticsMD Inc. stock remains steady Friday, still outperforms marketDecember 27, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gainsNovember 23, 2024 | marketwatch.comTherapeuticsMD Shifts Focus with Lower Q3 LossesNovember 14, 2024 | markets.businessinsider.comTherapeuticsMD Reports Reduced Losses Amid Strategic ShiftNovember 14, 2024 | markets.businessinsider.comTherapeuticsMD Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | finance.yahoo.comTherapeuticsMD Inc. stock remains steady Monday, underperforms marketNovember 12, 2024 | marketwatch.comTherapeuticsMD (NASDAQ:TXMD) Stock, Option ChainNovember 6, 2024 | benzinga.comTherapeuticsMD Inc. stock remains steady Wednesday, underperforms marketNovember 6, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gainsOctober 22, 2024 | marketwatch.comTherapeuticsMD Inc. stock remains steady Thursday, underperforms marketOctober 17, 2024 | marketwatch.comTherapeuticsMD Inc. stock remains steady Friday, underperforms marketOctober 11, 2024 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCUL, TXMD, EVFM, KMDA, and FLXN Company DescriptionsEvofem Biosciences NASDAQ:EVFM$0.01 0.00 (0.00%) As of 07/3/2025 11:39 AM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Flexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Kamada NASDAQ:KMDA$7.76 +0.02 (+0.21%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$7.78 +0.03 (+0.36%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Ocular Therapeutix NASDAQ:OCUL$9.36 -0.10 (-1.06%) Closing price 07/3/2025 01:45 PM EasternExtended Trading$9.62 +0.26 (+2.78%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.TherapeuticsMD NASDAQ:TXMD$1.12 -0.02 (-1.75%) Closing price 07/3/2025 03:37 PM EasternExtended Trading$1.14 +0.02 (+1.79%) As of 07/3/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
